Stockscreener 앱 받기
6.36
5.22%
-0.35
전일 마감가:
$6.71
열려 있는:
$6.76
하루 거래량:
531.37K
Relative Volume:
1.24
시가총액:
$73.96M
수익:
-
순이익/손실:
$-22.21M
주가수익비율:
-1.4619
EPS:
-4.3505
순현금흐름:
$-17.41M
1주 성능:
-20.90%
1개월 성능:
-6.61%
6개월 성능:
+67.81%
1년 성능:
+59.00%
1일 변동 폭
$6.20
$6.89
1주일 범위
$6.20
$8.20
52주 변동 폭
$3.20
$11.89
Cingulate Inc Stock (CING) Company Profile
명칭
Cingulate Inc
전화
(913) 942-2300
주소
1901 W. 47TH PLACE, KANSAS CITY
Compare CING vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
6.36 | 78.03M | 0 | -22.21M | -17.41M | -4.3505 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-10 | 개시 | ROTH MKM | Buy |
| 2023-12-22 | 다운그레이드 | Laidlaw | Buy → Hold |
Cingulate Inc 주식(CING)의 최신 뉴스
[EFFECT] Cingulate Inc. SEC Fi... | CING SEC FilingForm EFFECT - Stock Titan
Can Cingulate Inc Equity Warrant sustain earnings growthWeekly Trade Review & Trade Opportunity Analysis - baoquankhu1.vn
Cingulate Inc. Enters ATM Sales Agreement with A.G.P./Alliance Global Partners for Common Stock Offering – March 2026 - Minichart
Cingulate Announces ATM Equity Program and Share Issuance - TipRanks
Cingulate Inc has submitted a prospectus supplement to the U.S. Securities and Exchange Commission, planning to conduct a market offering and sell common shares in phases for a total amount of up to 100 million dollars. - Bitget
Cingulate (NASDAQ: CING) adds $100M ATM share sale capacity - Stock Titan
Cingulate Inc. (NASDAQ: CING) launches up to $100M ATM sales program - Stock Titan
Cingulate’s ADHD Drug Is Near An FDA Verdict - Finimize
Roth Capital Lowers Price Target for Cingulate (CING) to $14, Ma - GuruFocus
Roth Mkm Cuts Cingulate (NASDAQ:CING) Price Target to $14.00 - MarketBeat
Cingulate (NASDAQ: CING) files S-3/A amendment adding KPMG consent - Stock Titan
If You Invested $1,000 in Cingulate Inc (CING) - Stock Titan
History Review: Is Cingulate Inc likely to announce a buyback2026 Fundamental Recap & Low Volatility Stock Recommendations - baoquankhu1.vn
Cingulate Stock Snaps 2-Day Losing Streak As Roth Hikes Target On ADHD Drug Review; Retail Bets On Buyout Potential - MSN
What's going on with Cingulate stock today? - MSN
Cingulate stock jumps overnight: US Patent Office clears ADHD drug filing ahead of May FDA catalyst - MSN
Stock Report: How cyclical is Cingulate Inc Equity Warrants revenue stream2026 Valuation Update & Long Hold Capital Preservation Plans - baoquankhu1.vn
CING: Laying the Foundation for 1H:27 Launch - Research Tree
What's Going On With Cingulate Stock Today? - Benzinga
3.5M-share resale registration by Cingulate (NASDAQ: CING) under Lincoln Park deal - Stock Titan
Cingulate (NASDAQ:CING) Releases Quarterly Earnings Results, Misses Estimates By $0.28 EPS - MarketBeat
Cingulate (CING) Expected to Announce Earnings on Thursday - MarketBeat
Cingulate Reports 2025 Financial Results, Advances CTx-1301 ADHD Drug with New Patents and NDA Progress - Minichart
Cingulate Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights - Bitget
Why Is CING Stock Jumping Over 4% In Overnight Trading? - Stocktwits
Cingulate Inc. Advances Precision Timed Release ADHD and Anxiety Treatments with Innovative Drug Delivery Platform – 2025 Annual Report Highlights - Minichart
Cingulate (CING) outlines CTx-1301 FDA review, ADHD market and PTR pipeline - Stock Titan
Cingulate 10-K: $0 Revenue, $(22.45)M Net Loss - TradingView
PolyPid Approaches NDA Submission as New Medicare Model Creates Strong Incentives for SSI Prevention - Benzinga
CING: 2025 net loss widened to $22.4M as CTx-1301 advanced toward FDA review and $12M was raised - TradingView
CING: NDA for CTx-1301 accepted, $12M raised, and cash runway extends into late Q4 2026 - TradingView
CING: 2025 net loss widened to $22.4M; cash runway into late 2026, pending CTx-1301 FDA approval - TradingView
Patent wins and $12M PIPE support Cingulate (NASDAQ: CING) - Stock Titan
Cingulate Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Gains Report: How is Cingulate Inc managing supply chain issues2026 Macro Moves & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Why did Cingulate stock skyrocket today? - CryptoRank
Cingulate Stock Jumps Overnight: US Patent Office Clears ADHD Drug Filing Ahead Of May FDA Catalyst - Asianet Newsable
Cingulate (CING) CEO gets 6,862-share bonus grant, 2,959 withheld for tax - Stock Titan
Cingulate (CING) EVP awarded 4,526 shares; 1,828 withheld for taxes - Stock Titan
Cingulate (NASDAQ:CING) Trading Up 6.5%Here's What Happened - MarketBeat
How strong is Cingulate Inc. stock revenue growthPortfolio Gains Summary & Risk Controlled Stock Alerts - Naître et grandir
EPS Watch: Is Cingulate Inc currently under institutional pressureMarket Movers & Low Risk Growth Stock Ideas - baoquankhu1.vn
Fundamentals Check: Is Cingulate Inc likely to announce a buybackJuly 2025 Reactions & Consistent Growth Equity Picks - baoquankhu1.vn
Retail Trends: How cyclical is Cingulate Inc Equity Warrants revenue streamTrade Risk Report & Expert Verified Movement Alerts - baoquankhu1.vn
Can Cingulate Inc. stock rebound after recent weaknessNew Guidance & Free Technical Confirmation Trade Alerts - Naître et grandir
CING|Cingulate Inc|Price:6.430|Chg%:-0.13 - TradingKey
Cingulate (NASDAQ: CING) vote on 19% share issuance and warrants - Stock Titan
Pullback Watch: Is Cingulate Inc Equity Warrant a turnaround storyJuly 2025 Catalysts & Long-Term Growth Plans - baoquankhu1.vn
Risk Hedge: Can Cingulate Inc Equity Warrant maintain its current growth ratePrice Action & Daily Volume Surge Signals - baoquankhu1.vn
CING Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cingulate Inc (CING) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):